Results 121 to 130 of about 17,898,482 (301)
The carbocyclic Decitabine analog (cAzadC) incorporates as an antimetabolite weakly into the genome of growing tumor cells, where it triggers a genome‐wide demethylation and a surprisingly strong hydroxymethylation of cytosine, which translates into an efficient in vivo antitumor (AML) effect.
Maike Däther +17 more
wiley +2 more sources
This non‑enzymatic function of DHODH drives sunitinib resistance by competing with TRIM37 to block TRIM28 ubiquitination, thereby stabilizing TRIM28 and activating VEGFA transcription. Disrupting the DHODH–TRIM28 interaction with lisaftoclax restores drug sensitivity.
Shijie Qian +10 more
wiley +1 more source
Mitochondria‐Damaging Self‐Reporting Probe for Cancer Therapy
We developed a class of self‐reporting cationic chemotherapeutic probes that selectively induce mitochondrial damage and apoptosis in cancer cells. Their unique mitochondria‐to‐nucleus fluorescence migration enables real‐time visualization of the therapeutic process. ABSTRACT Mitochondrial damage induced by chemotherapeutic agents through disruption of
Hai Xu +10 more
wiley +2 more sources
Large‐Scale Machine Learning to Screen for Small‐Molecule Senolytics
A consistent workflow underpins all experiments in this study. A dedicated model‐selection dataset first identifies optimal hyperparameters for each algorithm. Models are then trained and rigorously evaluated on independent sets of molecules using the senolytic ratio SR. Comprehensive hyperparameter exploration across SMILES representations, task types,
Alexis Dougha +2 more
wiley +1 more source
BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains
The Bcl-2 family controls apoptosis by direct interactions of pro- and anti-apoptotic proteins. The principle mechanism is binding of the BH3 domain of pro-apoptotic proteins to the hydrophobic groove of anti-apoptotic siblings, which is therapeutically ...
Tobias B Beigl +13 more
doaj +1 more source
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez +17 more
wiley +1 more source
Citation: 'Bcl-2' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12945 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire +2 more sources
Unintended target effect of anti-BCL-2 DNAi
Abdul Shukkur Ebrahim,1 Mustapha Kandouz,2 Nada Emara,1 Amara B Sugalski,3 Leonard Lipovich,3 Ayad M Al-Katib1 1Lymphoma Research Laboratory, 2Department of Pathology, School of Medicine, 3Center for Molecular Medicine and Genetics, Wayne State ...
Ebrahim AS +5 more
core
ABSTRACT The transformation/transcription domain‐associated protein (TRRAP) gene encodes a large multidomain protein, a member of the phosphatidylinositol 3‐kinase‐related kinase (PIKK) family. TRRAP is a component of the histone acetyltransferase (HAT) complex, and it plays an important role in gene transcription, DNA repair, and cell‐cycle regulation.
Roseli Maria Zechi‐Ceide +10 more
wiley +1 more source
The extent of apoptosis and the expression of Bcl-2 was investigated in tumor samples from 165 women who underwent surgery for primary breast carcinoma between 1989 and 1990 in South-East Sweden.
P. Holmqvist, M. Lundström, O. Stål,
doaj +1 more source

